NCT01397240

The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients

The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients Taking Low-dose Aspirin, A Pilot Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to research the safety and efficacy of Albis® for the prevention of aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.

Detailed description

The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients taking Low-dose Aspirin, A pilot study Double-Blind, Placebo-Controlled, Randomized, Multicenter, Parallel, Prospective study

Conditions

• Patients Taking Low-dose Aspirin

Interventions

Type	Name	Description
DRUG	Albis Tab	2 Tab, twice a day, 12 weeks
DRUG	Placebo	2 Tab, twice a day, 12 weeks

Timeline

• Start date: 2011-07-01
• Primary completion: 2012-01-01
• Completion: 2013-06-01
• First posted: 2011-07-19
• Last updated: 2012-01-10

Locations

1 site across 1 country: South Korea